Dihydroartemisinin promotes angiogenesis during the early embryonic development of zebrafish

Ba, Qian; Duan, Juan; Tian, Jia-qiang; Wang, Ziliang; Chen, Tao; Li, Xiaoguang; Chen, Peizhan; Wu, Songjie; Li, Xiang; Li, Jingquan; Chu, Ruiai; Wang, Hui

doi:10.1038/aps.2013.48

Cited by 13 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, it seems that ART derivatives can arouse potential embryotoxicity in experimental animals. For example, dihydroartemisinin can bring about abnormal embryonic phenotypes and promote early embryonic angiogenesis in zebrafish [72]. Preclinical studies have demonstrated that artesunate can induce congenital malformations in rodents [73,74].…”

Section: Foregoing Researches On the Anticancer Effect Of Artemisimentioning

confidence: 99%

Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do?

et al. 2016

Molecules

View full text Add to dashboard Cite

Preclinical investigation and clinical experience have provided evidence on the potential anticancer effect of artemisinin and its derivatives (ARTs) in the recent two decades. The major mechanisms of action of ARTs may be due to toxic-free radicals generated by an endoperoxide moiety, cell cycle arrest, induction of apoptosis, and inhibition of tumor angiogenesis. It is very promising that ARTs are expected to be a new class of antitumor drugs of wide spectrum due to their detailed information regarding efficacy and safety. For developing repurposed drugs, many other characteristics of ARTs should be studied, including through further investigations on possible new pathways of anticancer effects, exploration on efficient and specific drug delivery systems-especially crossing biological barriers, and obtaining sufficient data in clinical trials. The aim of this review is to highlight these achievements and propose the potential strategies to develop ARTs as a new class of cancer therapeutic agents.

show abstract

Section: Foregoing Researches On the Anticancer Effect Of Artemisimentioning

confidence: 99%

Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do?

et al. 2016

Molecules

View full text Add to dashboard Cite

show abstract

“…Similar results have been observed in ovarian cancer cells in vitro and in vivo [95] . This group has also demonstrated the potential embryotoxicity of dihydroartemisinin in the embryos of wild-type and TG (flk1: GFP) transgenic zebrafish [96] .…”

Section: Introductionmentioning

confidence: 99%

Novel natural product therapeutics targeting both inflammation and cancer

Qin

Wang

Zhang

2017

Chinese Journal of Natural Medicines

View full text Add to dashboard Cite

Inflammation is recently recognized as one of the hallmarks of human cancer. Chronic inflammatory response plays a critical role in cancer development, progression, metastasis, and resistance to chemotherapy. Conversely, the oncogenic aberrations also generate an inflammatory microenvironment, enabling the development and progression of cancer. The molecular mechanisms of action that are responsible for inflammatory cancer and cancer-associated inflammation are not fully understood due to the complex crosstalk between oncogenic and pro-inflammatory genes. However, molecular mediators that regulate both inflammation and cancer, such as NF-κB and STAT have been considered as promising targets for preventing and treating these diseases. Recent works have further demonstrated an important role of oncogenes (e.g., NFAT1, MDM2) and tumor suppressor genes (e.g., p53) in cancer-related inflammation. Natural products that target these molecular mediators have shown anticancer and anti-inflammatory activities in preclinical and clinical studies. Sesquiterpenoids (STs), a class of novel plant-derived secondary metabolites have attracted great interest in recent years because of their diversity in chemical structures and pharmacological activities. At present, we and other investigators have found that dimeric sesquiterpenoids (DSTs) may exert enhanced activity and binding affinity to molecular targets due to the increased number of alkylating centers and improved conformational flexibility and lipophilicity. Here, we focus our discussion on the activities and mechanisms of action of STs and DSTs in treating inflammation and cancer as well as their structure-activity relationships.

show abstract

“…The zebrafish model was also used to test the potential embryotoxicity of DHA [ 52 ]. DHA exposure (1–10 µg/mL) during primitive hematopoiesis and hematopoietic stem cell specification caused an abnormal embryonic phenotype (pericardial edema, abnormal trunk axis, abnormal pigmentation), developmental delays or death, similarly to the other animal models.…”

Section: Developmental Toxicity Data Of Artemisinin Derivativesmentioning

confidence: 99%

Safety of Artemisinin Derivatives in the First Trimester of Pregnancy: A Controversial Story

et al. 2020

View full text Add to dashboard Cite

Artemisinin combination therapy (ACT) is recommended by the World Health Organization (WHO) as first line treatment for uncomplicated malaria both in adults and children. During pregnancy, ACT is considered safe only in the second and third trimester, since animal studies have demonstrated that artemisinin derivatives can cause foetal death and congenital malformation within a narrow time window in early embryogenesis. During this period, artemisinin derivatives induce defective embryonic erythropoiesis and vasculogenesis/angiogenesis in experimental models. However, clinical data on the safety profile of ACT in pregnant women have not shown an increased risk of miscarriage, stillbirth, or congenital malformation, nor low birth weight, associated with exposure to artemisinins in the first trimester. Although further studies are needed, the evidence collected up to now is prompting the WHO towards a change in the guidelines for the treatment of uncomplicated malaria, allowing the use of ACT also in the first trimester of pregnancy.

show abstract

Dihydroartemisinin promotes angiogenesis during the early embryonic development of zebrafish

Cited by 13 publications

References 28 publications

Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do?

Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do?

Novel natural product therapeutics targeting both inflammation and cancer

Safety of Artemisinin Derivatives in the First Trimester of Pregnancy: A Controversial Story

Contact Info

Product

Resources

About